share_log

Elevai Labs Inc. Announces Record-Breaking Sales Month in 2024 for Elevai Skincare Division

Elevai Labs Inc. Announces Record-Breaking Sales Month in 2024 for Elevai Skincare Division

Elevai Labs Inc. 宣佈Elevai護膚部門在2024年創下銷售記錄的月份
GlobeNewswire ·  12/04 21:00
  • Skincare Division Achieves New Sales Milestone, Enters Holiday Season with Strong Momentum
  • Strategic Restructuring Efforts Contributes to Achieving Record Monthly Sales and Sets Stage for Positive Projections for Year-End Growth
  • 護膚部門達成新銷售里程碑,以強勁的勢頭進入假日季節
  • 戰略重組工作促進了創紀錄的月度銷售,併爲年末增長的積極預測奠定了基礎

NEWPORT BEACH, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (Nasdaq: ELAB) ("Elevai", "Elevai Labs" or the "Company"), a diversified holding company, announces that its wholly owned subsidiary, Elevai Skincare Inc. ("Elevai Skincare"), has achieved a record-breaking month in sales for 2024, marking a significant milestone for the Company. This achievement underscores the success of transformational restructuring efforts led by Elevai Labs' new executive team and the adoption of a performance-driven culture.

加利福尼亞州紐波特海灘,2024年12月4日(環球新聞)—— Elevai Labs Inc.(納斯達克:ELAB)("Elevai"、"Elevai Labs"或"公司"),一家多元化控股公司,宣佈其全資子公司Elevai Skincare Inc.("Elevai Skincare")在2024年達成了創紀錄的銷售業績,標誌着公司的一個重要里程碑。這一成就突顯了Elevai Labs新管理團隊主導的變革性重組工作的成功,以及績效驅動文化的採納。

The milestone comes as the Elevai Skincare division heads into the holiday season with strong momentum, strengthened by strategic initiatives that have streamlined operations, enhanced productivity, and positioned the brand for continued growth. Elevai's management expressed its appreciation for the hard work and dedication of the Elevai Skincare operations team and sales force, who have demonstrated resilience in adapting to the newly implemented performance-based culture.

在假日季節進入的Elevai Skincare部門以強勁的勢頭取得了這一里程碑,此勢頭受到戰略舉措的支持,這些舉措優化了運營、提升了生產力,並使品牌適應了持續增長。Elevai的管理層對Elevai Skincare運營團隊和銷售團隊的辛勤工作和奉獻精神表示感激,他們在適應新實施的以績效爲基礎的文化中展現出了韌性。

Since taking leadership of Elevai Labs, the parent company of Elevai Skincare, in the third quarter of 2024, the new management team has prioritized operational efficiency, strategic sales growth, and a high-performance sales culture. These efforts culminated in the highest monthly revenue figures for Elevai Skincare in 2024, exceeding the previous four months average sales by 65%, paving the way for strong year-end performance. The new management team's focus on cost management and strategic initiatives has delivered higher revenue while reducing operating expenses, reaffirming their commitment to operational improvements with a desire to reach positive net profits.

自2024年第三季度接管Elevai Labs(Elevai Skincare的母公司)以來,新管理團隊已將運營效率、戰略銷售增長和高績效銷售文化置於優先地位。這些努力使Elevai Skincare在2024年實現了最高的月營業收入,超出了前四個月平均銷售額的65%,爲強勁的年末表現鋪平了道路。新管理團隊對成本管理和戰略舉措的關注在減少營業費用的同時,帶來了更高的營業收入,重申了他們對運營改善的承諾,並期望實現正的淨利潤。

Key drivers of success include:

成功的關鍵因素包括:

  • Sales Culture Transformation: Performance-based incentives and a results-oriented environment have driven motivation and accountability across the sales team.
  • Optimized Budgets and Marketing Strategies: Stringent budgeting and accountability measures have ensured efficient resource allocation. By prioritizing impactful campaigns, the sales team has strengthened relationships with core physician-dispensed channels and driven disciplined, sustainable growth.
  • Integrated Marketing and Sales Objectives: Improved collaboration between marketing and sales teams has aligned campaigns with sales goals, enhancing lead generation and conversion outcomes.
  • Targeted Training Programs: Comprehensive training programs for both the sales team and physician-dispensed customers have bolstered advanced product knowledge, improved patient recommendation strategies, and strengthened clinic partnerships.
  • 銷售文化轉型:以績效爲基礎的激勵措施和以結果爲導向的環境推動了銷售團隊的動機和責任感。
  • 優化的預算和市場策略:嚴格的預算和責任措施確保了資源的有效配置。通過優先考慮有影響力的活動,銷售團隊加強了與核心醫生派發渠道的關係,並實現了有序、可持續的增長。
  • 整合的市場和銷售目標:市場團隊與銷售團隊之間的協作改善使活動與銷售目標對齊,從而增強線索生成和轉化結果。
  • 針對性的培訓項目:對銷售團隊和醫生派發客戶的全面培訓項目增強了先進的產品知識,改善了患者推薦策略,鞏固了診所合作伙伴關係。

Preliminary unaudited sales data for Elevai Skincare for November 2024 reflects revenue of $300K significantly higher than monthly figures earlier in the year:

2024年11月Elevai Skincare的初步未經審計的銷售數據反映出營業收入爲30萬,比年初的月度數據顯示顯著增加:

  • July: $160K
  • August: $199K
  • September: $168K
  • October: $198K
  • 七月:$160K
  • 八月:$199K
  • 九月:$168K
  • 十月:$198K

Positioned for Continued Growth
Elevai Skincare's strong performance aligns with the Company's overarching goal of creating shareholder value through operational excellence and strategic growth across its subsidiaries. With strong momentum entering the holiday season, the Company is well-positioned to drive further success as it closes out the year.

爲持續增長做好準備
Elevai護膚品的強勁表現與公司的總體目標相一致,即通過卓越的運營和在其子公司的戰略增長來爲股東創造價值。隨着假日季節的強勁勢頭,該公司爲在年底取得更多成功做好了充分準備。

About Elevai Labs, Inc.

關於Elevai Labs, Inc.

Elevai Labs Inc. (NASDAQ: ELAB) specializes in medical aesthetics and biopharmaceutical drug development, focusing on innovations for skin aesthetics and treatments tied to obesity and metabolic health. The Company operates a diverse portfolio of three wholly owned subsidiaries across the medical aesthetics and biopharmaceutical sectors, Elevai Skincare Inc., Elevai Biosciences Inc., and Elevai Research Inc. For more information please visit .

Elevai實驗室公司(納斯達克股票代碼:ELAB)專注於醫療美學和生物製藥藥物的研發,致力於皮膚美學和與肥胖及代謝健康相關的治療創新。該公司在醫療美學和生物製藥領域擁有三家全資子公司的多樣化組合,分別爲Elevai護膚公司,Elevai生命科學公司和Elevai研究公司。更多信息請訪問。

About Elevai Skincare Inc.

關於Elevai護膚公司。

A subsidiary of Elevai, Elevai Skincare is a medical aesthetics company developing and commercializing cutting-edge physician-dispensed skin and hair care applications that focuses on science-backed applications for the physician-dispensed market, utilizing cutting-edge technologies to redefine skincare and hair care, including its stem cell exosome technology. For more information, please visit elevaiskincare.com.

Elevai的子公司Elevai護膚是一家醫療美容公司,專注於開發和商業化尖端的醫生分銷皮膚和頭髮護理應用,致力於科學支持的醫生分銷市場應用,結合尖端科技重新定義護膚和頭髮護理,包括其幹細胞外泌體技術。欲了解更多信息,請訪問elevaiskincare.com。

Forward-Looking Statements

前瞻性聲明

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "believes," "expects," "plans," "potential," "would" and "future" or similar expressions such as "look forward" are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These risks and uncertainties include, among others: Elevai's limited operating history and historical losses; Elevai's ability to raise additional funding to complete the development and any commercialization of its product candidates; Elevai's dependence on the success of its product candidates EL-22 and EL-32; that Elevai may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; Elevai's ability to obtain, maintain and protect its intellectual property; Elevai's dependence on third parties in connection with manufacturing, clinical trials and preclinical studies; and Elevai's expectations regarding its growth, strategy, progress and the design, objectives and timing of its studies. These and other risks are described more fully in Elevai's filings with the United States Securities and Exchange Commission ("SEC"), including the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

本新聞稿中涉及的非歷史事實事項的陳述屬於1995年私營證券訴訟改革法案(已修訂)所指的「前瞻性陳述」。諸如「相信」、「期望」、「計劃」、「潛在」、「會」和「未來」或類似的表達如「期待」等旨在識別前瞻性陳述。前瞻性陳述是在本新聞稿發佈日期作出的,既不是歷史事實,也不是未來表現的保證。相反,這些陳述僅基於我們對未來業務、未來計劃和策略、預測、預期事件和趨勢、經濟、監管機構的活動及未來的法規和其他未來條件的當前信念、期望和假設。由於前瞻性陳述與未來相關,因此它們受到固有的不確定性、風險和環境變化的影響,這些因素無法預測,並且許多因素超出了我們的控制範圍。儘管公司相信這些前瞻性陳述中表達的期望是合理的,但無法保證這些期望將會得到確認,公司提醒投資者,實際結果可能與預期結果有重大差異。因此,您不應依賴任何這些前瞻性陳述。這些風險和不確定性包括但不限於:Elevai有限的運營歷史和歷史虧損;Elevai籌集額外資金以完成其產品候選者的開發和商業化的能力;Elevai對其產品候選者EL-22和EL-32成功的依賴;Elevai可能在啓動、招募或完成任何臨床試驗方面延遲;來自開發類似用途產品的第三方的競爭;Elevai獲得、維護和保護其知識產權的能力;Elevai在製造、臨床試驗和臨床前研究方面對第三方的依賴;以及Elevai對其增長、戰略、進展及其研究的設計、目標和時間的期望。這些和其他風險在Elevai向美國證券交易委員會(「SEC」)提交的文件中有更詳細的描述,包括公司截至2023年12月31日的年度報告的「風險因素」部分,該報告於2024年3月29日提交給SEC,以及其隨後提交給或提供給SEC的其他文件。投資者和證券持有者被敦促免費在SEC的官方網站www.sec.gov上查閱這些文件。本新聞稿中包含的所有前瞻性陳述僅反映它們被作出的日期。除法律要求的程度外,公司沒有義務更新這些陳述以反映在作出這些陳述後的事件或環境。

IR Contact:
IR@ElevaiLabs.com

IR聯繫方式:
IR@ElevaiLabs.com


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論